(241) The Health Economics of Metastatic Hormone Sensitive and Non-Metatastatic Castration-Resistant Prostate Cancer – A Systematic Literature Review

Saturday, August 27, 2022

8:00 AM – 6:00 PM CEST

Location: Hall C

Publication Number: 915

Presenting Author(s)

Ivan Yanev, PhD(c)
– Student, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

Co-Author(s)

Alice Dragomir
– McGill University, Montreal, QC, Canada
Jessy Gatete Jr
– McGill University, QC, Canada

Background: Health economic evaluations are needed to assess the impact on the healthcare system of emerging treatment patterns for advanced prostate cancer. The objective of this study is to review the scientific literature identifying cost-effectiveness and cost analyses that are assessing treatments for metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC).

Methods: On June 29, 2021, we searched the scientific (MEDLINE, Embase, and EBSCO) and grey literature for health economic studies targeting mHSPC and nmCRPC. We used an extraction form based on Wijnen and al. 2016, the CHEC-extended checklist, and the Welte checklist for data extraction, risk of bias assessment, and transferability analysis, respectively.

Results: We retained 20 cost-effectiveness and 4 cost analyses in the mHSPC setting, and 14 cost-effectiveness and 6 cost analyses in the nmCRPC setting. Docetaxel in combination with androgen deprivation therapy (ADT) was the most cost-effective treatment in the mHSPC setting. Apalutamide, darolutamide, and enzalutamide presented similar results vs ADT alone and were identified as cost-effective treatments for nmCRPC. An increase in costs as patients transitioned from nmCRPC to mCRPC was noted.

Conclusions: We concluded that there is an important unmet need for health economic evaluations in the mHSPC and nmCRPC setting incorporating real-world data to support healthcare decision-making.